This product is for Professional Use only and not for sale to the general public for home use.
Please log in with a business account to purchase.
Anti-Isocitrate dehydrogenase 1 human hamster IDH1 mouse monoclonal primary antibody clone RMab-3 ELISA Western Blotting WB Immunochemistry IC Wako
Product code: 014-24061
Pack Size: 100µg
CE Verified: Research Use Only
Contact us
This is not a regular stock item and therefore not subject to our standard delivery schedule. Please contact us on +44 (0) 2380 483000 for advice on expected delivery date.
Product Information
Anti-Isocitrate Dehydrogenase 1 (IDH1) produced by Wako Pure Chemicals.
Isocitrate dehydrogenase (IDH) is an oxidoreductase that catalyses the oxidative decarboxylation of isocitrate producing α-ketoglutarate and carbon dioxide. There are three isoforms of IDH, IDH3 is NAD+ dependent and catalyses the third step of the tricarboxylic acid (TCA) cycle within the mitochondria matrix. The IDH1 and IDH2 isoforms use NADP+ as a cofactor and are primarily located in the cytoplasm and mitochondria respectively. In addition to their catabolic potential in the TCA cycle the IDH1 and IDH2 isoforms also serve to shuttle electrons between the mitochondria and cytosol and play a role in cellular defence against oxidative damage. Mutations in the IDH1 and IDH2 isoforms have been reported in some cancers.
Gliomas are tumours that start in the brain or spine with varying malignancy. Astrocytomas are one of the most common forms of primary brain tumour that develop in astrocytes, an abundant subset of glial cells in the nervous system that serve a number of structural and biochemical support roles. There is a WHO classification for grading astrocytomas with regard to malignancy from Pilocytic astrocytoma (Grade I) and Diffuse astrocytoma (Grade II) to Anaplastic astrocytoma (Grade III) and Glioblastoma (Grade IV).
Frequent mutations of Isocitrate dehydrogenase (IDH) have been reported in grad II/III glioma or in stage IV glioblastoma that has developed from low-grade gliomas, most commonly the mutations are seen in IDH1 (arginine residue 132) and IDH2 (arginine residue 172). Other IDH1 mutations include R132H, R132S, R132G, R132C and R132L.
This monoclonal antibody detects wild type and mutated IDH1 suitable for use in ELISA, Western Blot and immunochemistry applications.
Cross reacts with human, mouse and hamster IDH1.
Clone: RMab-3
Host: Mouse
Isotype: IgG1
Source: Purified from hybridoma supernatant using protein G agarose
Concentration: indicated on vial label
Formulation: PBS (pH 7.2) containing 0.05% sodium azide
Suggested dilutions:
ELISA: 1-5µg/ml
Western Blot: 5µg/ml
Immunohistochemistry: 5-10µg/ml
Store -20°C.
Isocitrate dehydrogenase (IDH) is an oxidoreductase that catalyses the oxidative decarboxylation of isocitrate producing α-ketoglutarate and carbon dioxide. There are three isoforms of IDH, IDH3 is NAD+ dependent and catalyses the third step of the tricarboxylic acid (TCA) cycle within the mitochondria matrix. The IDH1 and IDH2 isoforms use NADP+ as a cofactor and are primarily located in the cytoplasm and mitochondria respectively. In addition to their catabolic potential in the TCA cycle the IDH1 and IDH2 isoforms also serve to shuttle electrons between the mitochondria and cytosol and play a role in cellular defence against oxidative damage. Mutations in the IDH1 and IDH2 isoforms have been reported in some cancers.
Gliomas are tumours that start in the brain or spine with varying malignancy. Astrocytomas are one of the most common forms of primary brain tumour that develop in astrocytes, an abundant subset of glial cells in the nervous system that serve a number of structural and biochemical support roles. There is a WHO classification for grading astrocytomas with regard to malignancy from Pilocytic astrocytoma (Grade I) and Diffuse astrocytoma (Grade II) to Anaplastic astrocytoma (Grade III) and Glioblastoma (Grade IV).
Frequent mutations of Isocitrate dehydrogenase (IDH) have been reported in grad II/III glioma or in stage IV glioblastoma that has developed from low-grade gliomas, most commonly the mutations are seen in IDH1 (arginine residue 132) and IDH2 (arginine residue 172). Other IDH1 mutations include R132H, R132S, R132G, R132C and R132L.
This monoclonal antibody detects wild type and mutated IDH1 suitable for use in ELISA, Western Blot and immunochemistry applications.
Cross reacts with human, mouse and hamster IDH1.
Clone: RMab-3
Host: Mouse
Isotype: IgG1
Source: Purified from hybridoma supernatant using protein G agarose
Concentration: indicated on vial label
Formulation: PBS (pH 7.2) containing 0.05% sodium azide
Suggested dilutions:
ELISA: 1-5µg/ml
Western Blot: 5µg/ml
Immunohistochemistry: 5-10µg/ml
Store -20°C.
Specification
- Brand FUJIFILM Wako Chemicals Europe GmbH – Lab Chem
- Sterile N
- CE Certified Research Use Only
- Warranty Period Standard Terms Apply
- Is product classified as dangerous goods? No
- Does the product contain latex? Unspecified
- Host Mouse
- Clonality Monoclonal
- Application ELISA, Western Blotting WB< Immunohistochemistry IHC)
- Form 100µg
- Specificity Wild and mutated IDH1
- Species Reactivity human, mouse and hamster
- Preparation Form PBS (pH 7.2) containing 0.05% sodium azide
- Concentration lot dependent
- Clone Number RMab-3
- Isotype IgG1
- Source Species Mouse
- Shelf Life NULL
- Cross Reactivity human, mouse and hamster IDH1
- Immunogen NULL
Storage Details
- Pack Description 100µg
- Shipping Condition Dry Ice
- Storage Condition -20
- Pack Length (m) 0.0015
- Pack Width (m) 0.0015
- Pack Height (m) 0.0022
- Pack Weight (kg) 0.00